May 2, 2013

Trading of AVEO Common Stock Halted

Download PDF

FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

AVEO Conference Call Today at 4:30 p.m. ET

CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 2, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May 2, 2013. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) meets today to discuss the New Drug Application (NDA) for tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC). According to the timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the NDA is expected to be complete by July 28, 2013.

Today’s Conference Call and Webcast Reminder

The AVEO management team will host a conference call today at 4:30 p.m. (ET) to discuss the ODAC panel’s review of the tivozanib NDA. The call can be accessed by dialing 1-866-730-5771 (domestic) or 1-857-350-1595 (international) five minutes prior to the start of the call and providing the passcode 79239089. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 70099254. The replay will be available for two weeks from the date of the call.

A webcast of the conference call can also be accessed by visiting the investors section of the AVEO website at A replay of the webcast will be archived on the company’s website for two weeks following the call.

About AVEO

AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company’s website at

Source: AVEO Oncology

Pure Communications
Investor Contact:
Caton Morris, 910-232-7166
Media Contact:
AVEO Oncology
Rob Kloppenburg, 617-930-5595
Pure Communications
Dan Budwick, 973-271-6085